• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

类器官的前景与挑战:从人源化到人类来源。

Promises and challenges of organoids: From humanized to human derived.

机构信息

Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China; State Key Laboratory of Molecular Oncology, Tsinghua University, Beijing 100084, China.

出版信息

Cell Stem Cell. 2024 Mar 7;31(3):281-282. doi: 10.1016/j.stem.2024.02.002.

DOI:10.1016/j.stem.2024.02.002
PMID:38458173
Abstract

Kastenschmidt et al. present a groundbreaking organoid culture model for follicular lymphoma, which is capable of maintaining stable compositions of B and T cells. This model is utilized in testing bispecific antibodies in effective killing of tumor B cells with the activation of T cells.

摘要

卡斯滕施密特等人提出了一种滤泡性淋巴瘤的开创性类器官培养模型,该模型能够维持 B 细胞和 T 细胞的稳定组成。该模型用于测试双特异性抗体,以有效杀死肿瘤 B 细胞并激活 T 细胞。

相似文献

1
Promises and challenges of organoids: From humanized to human derived.类器官的前景与挑战:从人源化到人类来源。
Cell Stem Cell. 2024 Mar 7;31(3):281-282. doi: 10.1016/j.stem.2024.02.002.
2
Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies.用于评估 T 细胞双特异性抗体的免疫浸润肾类器官芯片模型。
Proc Natl Acad Sci U S A. 2023 Aug 29;120(35):e2305322120. doi: 10.1073/pnas.2305322120. Epub 2023 Aug 21.
3
Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.三维结直肠癌类器官模型对 CEA-CD3 T 细胞结合物的反应。
Theranostics. 2022 Jan 1;12(3):1373-1387. doi: 10.7150/thno.63359. eCollection 2022.
4
Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.在接受CD3xCD19双特异性抗体、CD28单特异性抗体和自体T细胞治疗的严重联合免疫缺陷小鼠中预防爱泼斯坦-巴尔病毒诱导的人B细胞淋巴瘤。
Cancer Res. 1997 May 1;57(9):1704-9.
5
Immunity War: A Novel Therapy for Lymphoma Using T-cell Bispecific Antibodies.免疫战争:利用 T 细胞双特异性抗体治疗淋巴瘤的新疗法。
Clin Cancer Res. 2018 Oct 1;24(19):4631-4632. doi: 10.1158/1078-0432.CCR-18-1363. Epub 2018 Jun 8.
6
A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells.一种双特异性单链抗体,可介导靶细胞限制性、超激动性CD28刺激并杀伤淋巴瘤细胞。
Leukemia. 2009 Jan;23(1):71-7. doi: 10.1038/leu.2008.271. Epub 2008 Oct 2.
7
Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.使用CD3xCD19双特异性抗体和CD28共刺激对低度B细胞淋巴瘤进行局部区域治疗。II. 细胞免疫反应评估
Int J Cancer. 2001 Feb 15;91(4):516-22. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1069>3.0.co;2-a.
8
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.抗 CD20/CD3 T 细胞依赖的双特异性抗体用于治疗 B 细胞恶性肿瘤。
Sci Transl Med. 2015 May 13;7(287):287ra70. doi: 10.1126/scitranslmed.aaa4802.
9
Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.间充质基质细胞作为四价双特异性Tandab(CD3/CD19)的载体用于治疗B细胞淋巴瘤,并联合吲哚胺2,3-双加氧酶(IDO)途径抑制剂D-1-甲基色氨酸
J Hematol Oncol. 2017 Feb 23;10(1):56. doi: 10.1186/s13045-017-0397-z.
10
[Cancer therapy using bispecific antibodies].[使用双特异性抗体的癌症治疗]
Rinsho Ketsueki. 2018;59(10):1942-1947. doi: 10.11406/rinketsu.59.1942.

引用本文的文献

1
Modeling development of breast cancer: from tumor microenvironment to preclinical applications.乳腺癌发展建模:从肿瘤微环境到临床前应用
Front Pharmacol. 2024 Dec 4;15:1466017. doi: 10.3389/fphar.2024.1466017. eCollection 2024.